BioTrinity Presentation Available Online

1 May 2020

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum Presentation at BioTrinity 2020 Available on Company Website

Sareum Holdings plc (AIM:SAR), the specialist small molecule drug development business, announces that, further to its announcement of 28 April 2020, the Company's virtual presentation, including the video content, given by its CEO, Dr Tim Mitchell, at BioTrinity 2020 (28 April - 1 May 2020) can now be viewed via the Company's website, www.sareum.com and at bit.ly/3aMVo8Z.

For further information, please contact: 

Sareum Holdings plc

Tim Mitchell, CEO                                                             01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / Richard Tulloch                                      020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce / John Beresford-Peirse                          020 3764 2341

Citigate Dewe Rogerson (Financial PR)

Mark Swallow/ David Dible                                           020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting completion of preclinical development for each molecule in 2020.

The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc., which is currently seeking to on-license SRA737 to a third party for further development.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.

- Ends -